Mo Hong-Nan, Liu Peng
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chronic Dis Transl Med. 2017 Jul 19;3(3):148-153. doi: 10.1016/j.cdtm.2017.06.002. eCollection 2017 Sep.
encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. exon 14 alterations and gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have been evaluated in clinical trials. In patients with advanced non-small cell lung cancer, cabozantinib and crizotinib showed clear efficacy with a generally tolerable adverse events profile. In gastrointestinal cancers, most phase III trials of MET inhibitors showed negative results. In hepatocellular carcinoma, based on the encouraging results of some phase II studies, a series of phase III trials are currently recruiting patients to access the efficacy and safety of inhibitors.
编码肝细胞生长因子（HGF）的受体酪氨酸激酶c-MET。c-MET与HGF的特定组合激活下游信号通路，以触发细胞迁移、增殖和血管生成。外显子14改变和基因扩增在癌症起源中起关键作用。几种c-MET的单克隆抗体和小分子抑制剂已在临床试验中进行评估。在晚期非小细胞肺癌患者中，卡博替尼和克唑替尼显示出明显疗效，且不良事件总体上可耐受。在胃肠道癌症中，大多数MET抑制剂的III期试验结果为阴性。在肝细胞癌中，基于一些II期研究的令人鼓舞的结果，一系列III期试验目前正在招募患者，以评估抑制剂的疗效和安全性。
